紫杉醇/奥沙利铂/5-氟尿嘧啶联合治疗31例晚期或转移性胃癌  

An observation study of paclitaxel/oxaliplatin/fluorouracil regimen in patients with advanced/metastatic gastric cancer

作　　者：王兴元[1] 冯奉仪[1] 张频[1] 董梅[1] 何静[1] 罗扬[1] 周生余[1] 罗志国[1] 邢铺元[1] 

机构地区：[1]中国医学科学院中国协和医科大学肿瘤医院内科,北京100021

出　　处：《中国新药杂志》2005年第8期1049-1051,共3页Chinese Journal of New Drugs

摘　　要：目的:观察紫杉醇/奥沙利铂/5-氟尿嘧啶方案治疗晚期或转移性胃癌的客观疗效、疾病进展时间、生存时间和毒性反应.方法:入选31例晚期或转移性胃癌患者接受紫杉醇80～100 mg·m-2(d1,d8), 奥沙利铂130 mg·m-2(d2), 5-氟尿嘧啶 400～500 mg·m-2(d2～6), 21 d为1周期,疗程2～6周期.结果:总有效率为51.6%,中位疾病进展时间(TTP )为5个多月, 中位生存时间(MST)为13个月, 1年生存率为41.9%,2年生存率为13%.常见的毒性反应为白细胞和中性粒细胞减低、腹泻和周围神经毒性反应等.结论:紫杉醇/奥沙利铂/5-氟尿嘧啶联合化疗方案治疗晚期或转移性胃癌的疗效显著、耐受性较好.Objective： To evaluate the objective response rate, time to progression （TrP）, survival time, and toxicity of paclitaxel/oxaliplatin/fluorouracil regimen in patients with advanced or metastatic gastric cancer. Methods：31 patients with advanced and metastatic gastric cancer were administrated with paclitaxel 80 - 100 mg·m^-2 （d1, d8）, oxaliplatin 130 mg·m^-2 （ d2）, and fluorouracil 400 - 500 mg·m^-2 （d2 - 6） in a 21-day cycle of therapy for 2 - 6 cycles. Results ： The outcomes of the regimen was as follows ： response rate 51.6%, median TIP more than 5 months, median survival time 13 months, 1 year survival rate 41.9%, and 2 years survival rate 13%. The most common adverse effects were leucopenia, neutropenia, diarrhea and peripheral neuropathy. Conclusion： The paclitaxel/oxaliplatin/fluorouracil regimen offers a better therapeutic option in patients with advanced and metastatic gastric cancer.

关 键 词：紫杉醇 奥沙利铂 5-氟尿嘧啶 胃癌 

分 类 号：R969.4[医药卫生—药理学] R979.1[医药卫生—药学]